Offered by: Nemours Children's
Locations: Delaware Valley
A Phase 2 Multicenter Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
What is the trial about?
To look at the survival rate when a drug called dasatinib is added to standard chemotherapy.
Who can participate?
Age > 1 year and < 18
What is involved?
Length of study is approximately 7 years. Tests and procedures to be done include: Review of medical history; Complete physical exam; Assessment of performance status; Chest X-ray; ECG; ECHO); Collection of blood and urine samples; Spinal tap; DXA; minimal residual disease test; pregnancy test.